The polycystic ovary syndrome: a position statement from the European Society of Endocrinology

Eur J Endocrinol. 2014 Oct;171(4):P1-29. doi: 10.1530/EJE-14-0253. Epub 2014 May 21.


Polycystic ovary syndrome (PCOS) is the most common ovarian disorder associated with androgen excess in women, which justifies the growing interest of endocrinologists. Great efforts have been made in the last 2 decades to define the syndrome. The presence of three different definitions for the diagnosis of PCOS reflects the phenotypic heterogeneity of the syndrome. Major criteria are required for the diagnosis, which in turn identifies different phenotypes according to the combination of different criteria. In addition, the relevant impact of metabolic issues, specifically insulin resistance and obesity, on the pathogenesis of PCOS, and the susceptibility to develop earlier than expected glucose intolerance states, including type 2 diabetes, has supported the notion that these aspects should be considered when defining the PCOS phenotype and planning potential therapeutic strategies in an affected subject. This paper offers a critical endocrine and European perspective on the debate on the definition of PCOS and summarises all major aspects related to aetiological factors, including early life events, potentially involved in the development of the disorder. Diagnostic tools of PCOS are also discussed, with emphasis on the laboratory evaluation of androgens and other potential biomarkers of ovarian and metabolic dysfunctions. We have also paid specific attention to the role of obesity, sleep disorders and neuropsychological aspects of PCOS and on the relevant pathogenetic aspects of cardiovascular risk factors. In addition, we have discussed how to target treatment choices based according to the phenotype and individual patient's needs. Finally, we have suggested potential areas of translational and clinical research for the future with specific emphasis on hormonal and metabolic aspects of PCOS.

Publication types

  • Practice Guideline
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Androgens / metabolism*
  • Bariatric Surgery
  • Biomarkers / blood
  • Body Composition
  • Cardiovascular Diseases / etiology*
  • Cardiovascular Diseases / metabolism
  • Cardiovascular Diseases / prevention & control
  • Concept Formation
  • Female
  • Glucose / metabolism
  • Glucose Intolerance / etiology
  • Glucose Intolerance / metabolism
  • Gonadal Steroid Hormones / metabolism
  • Humans
  • Hypoglycemic Agents / therapeutic use
  • Infertility, Female / etiology*
  • Infertility, Female / metabolism
  • Infertility, Female / therapy
  • Insulin Resistance
  • Lipid Peroxidation
  • Obesity / complications
  • Obesity / etiology*
  • Obesity / metabolism
  • Obesity / therapy
  • Ovary / diagnostic imaging
  • Ovary / metabolism*
  • Ovary / pathology*
  • Phenotype
  • Polycystic Ovary Syndrome* / complications
  • Polycystic Ovary Syndrome* / diagnosis
  • Polycystic Ovary Syndrome* / etiology
  • Polycystic Ovary Syndrome* / metabolism
  • Polycystic Ovary Syndrome* / psychology
  • Polycystic Ovary Syndrome* / therapy
  • Quality of Life
  • Risk Reduction Behavior
  • Testosterone / metabolism*
  • Ultrasonography


  • Androgens
  • Biomarkers
  • Gonadal Steroid Hormones
  • Hypoglycemic Agents
  • Testosterone
  • Glucose